Cite
Pedersen-Bjergaard U, Agesen RM, Brøsen JMB, et al. Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open-label, crossover trial. Diabetes Obes Metab. 2021;24(2):257-267doi: 10.1111/dom.14574.
Pedersen-Bjergaard, U., Agesen, R. M., Brøsen, J. M. B., Alibegovic, A. C., Andersen, H. U., Beck-Nielsen, H., Gustenhoff, P., Hansen, T. K., Hedetoft, C., Jensen, T. J., Juhl, C. B., Jensen, A. K., Lerche, S. S., Nørgaard, K., Parving, H. H., Sørensen, A. L., Tarnow, L., & Thorsteinsson, B. (2022). Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open-label, crossover trial. Diabetes, obesity & metabolism, 24(2), 257-267. https://doi.org/10.1111/dom.14574
Pedersen-Bjergaard, Ulrik, et al. "Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open-label, crossover trial." Diabetes, obesity & metabolism vol. 24,2 (2022): 257-267. doi: https://doi.org/10.1111/dom.14574
Pedersen-Bjergaard U, Agesen RM, Brøsen JMB, Alibegovic AC, Andersen HU, Beck-Nielsen H, Gustenhoff P, Hansen TK, Hedetoft C, Jensen TJ, Juhl CB, Jensen AK, Lerche SS, Nørgaard K, Parving HH, Sørensen AL, Tarnow L, Thorsteinsson B. Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open-label, crossover trial. Diabetes Obes Metab. 2022 Feb;24(2):257-267. doi: 10.1111/dom.14574. Epub 2021 Nov 02. PMID: 34643020.
Copy
Download .nbib